Clinical Cancer Research, Vol 2, Issue 1 107-118, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma

JA Houghton, PJ Cheshire, JD Hallman 2nd, L Lutz, X Luo, Y Li and PJ Houghton
Departments of Molecular Pharmacology and Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee 38101, USA.

Irinotecan [7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothec in] administered i.v. in two courses, each course consisting of administration every day for 5 days [(dx5)2] on days 1-5 and 8-12, has demonstrated significant activity against advanced human tumor xenografts derived from colon adenocarcinomas and several childhood cancers. To build on this therapy, we have evaluated the combination of irinotecan given on this schedule with 5-fluorouracil given on days 1, 7, and 14 with or without leucovorin [(dx5)3 i.v.] against colon tumors, or combined with etoposide administered (dx5)2 i.v. either 2 h before or 2 h after irinotecan for treatment of colon tumors and rhabdomyosarcomas. A combination of 5-fluorouracil at 75% and irinotecan at 50% of their respective maximum tolerated doses when administered as single agents on this schedule gave acceptable toxicity. Against colon adenocarcinoma xenografts, 5-fluorouracil did not enhance the response rate compared with that obtained with the optimum dose of irinotecan given as a single agent. Against GC3/TK- xenografts, which lack thymidine kinase and cannot salvage thymidine to circumvent the inhibition of thymidylate synthase, the addition of leucovorin to the combination increased the complete response rate from 10 to >90%, whereas the response rates for the optimal doses of irinotecan or 5-fluorouracil, as single agents, were 30 and <10%, respectively. Etoposide d x 5 i.v. for two or three courses or (d x 5)3 p.o. did not cause objective regression of any colon tumors. In contrast, three of five rhabdomyosarcoma lines demonstrated a high frequency of partial regressions or complete regressions when treated (d x 5)1 i.v. Repetitive courses [e.g., (d x 5)2 or (d x 5)3] i.v. or p.o. or by 4-h infusion d x3 i.v. were either equally effective or less effective. Irinotecan and etoposide were combined using the (d x 5)2 i.v. schedule for both drugs, in which irinotecan was given 2 h before or 2 h after the administration of etoposide. Each drug could be combined at only 38% of its respective maximum tolerated dose when administered as a single agent, indicating greater than additive toxicity. Toxicity was similar irrespective of the sequence of administration and was manifested by loss of weight (73% of the initial weight, nadir day 7), myelosuppression, and prolonged thrombocytopenia. The responses of colon carcinomas to the combination given in either sequence were similar to that achieved with irinotecan given alone at the same dose as used in the combination. Similarly, when etoposide was given before irinotecan, the responses of rhabdomyosarcomas were similar to those for irinotecan. However, in experiments in which etoposide was administered 2 h after each dose of irinotecan, there was significant antagonism of the antitumor activity of irinotecan.

This article has been cited by other articles:

				I. Okamoto, T. Nishimura, M. Miyazaki, H. Yoshioka, A. Kubo, K. Takeda, N. Ebi, S. Sugawara, N. Katakami, M. Fukuoka, et al. Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 Clin. Cancer Res., August 15, 2008; 14(16): 5250 - 5254. [Abstract] [Full Text] [PDF]

				K. J. Yoon, J. Qi, J. S. Remack, K. G. Virga, M. J. Hatfield, P. M. Potter, R. E. Lee, and M. K. Danks Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. Mol. Cancer Ther., June 1, 2006; 5(6): 1577 - 1584. [Abstract] [Full Text] [PDF]

				M. Ciomei, V. Croci, A. Ciavolella, D. Ballinari, and E. Pesenti Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. Clin. Cancer Res., May 1, 2006; 12(9): 2856 - 2861. [Abstract] [Full Text] [PDF]

				M. A. Wright, G. Morrison, P. Lin, G. D. Leonard, D. Nguyen, X. Guo, E. Szabo, J. L. Hopkins, J. P. Leguizamo, N. Harold, et al. A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors Clin. Cancer Res., June 1, 2005; 11(11): 4144 - 4150. [Abstract] [Full Text] [PDF]

				R. M. Wadkins, J. L Hyatt, K. J. P. Yoon, C. L. Morton, R. E. Lee, K. Damodaran, P. Beroza, M. K. Danks, and P. M. Potter Discovery of Novel Selective Inhibitors of Human Intestinal Carboxylesterase for the Amelioration of Irinotecan-Induced Diarrhea: Synthesis, Quantitative Structure-Activity Relationship Analysis, and Biological Activity Mol. Pharmacol., June 1, 2004; 65(6): 1336 - 1343. [Abstract] [Full Text] [PDF]

				A. Falcone, G. Masi, G. Allegrini, R. Danesi, E. Pfanner, I. M. Brunetti, A. Di Paolo, S. Cupini, M. Del Tacca, and P. Conte Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., October 1, 2002; 20(19): 4006 - 4014. [Abstract] [Full Text] [PDF]

				A. Falcone, A. Di Paolo, G. Masi, G. Allegrini, R. Danesi, M. Lencioni, E. Pfanner, S. Comis, M. Del Tacca, and P. Conte Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients J. Clin. Oncol., August 1, 2001; 19(15): 3456 - 3462. [Abstract] [Full Text] [PDF]

				C. L. Morton, M. Wierdl, L. Oliver, M. K. Ma, M. K. Danks, C. F. Stewart, J. L. Eiseman, and P. M. Potter Activation of CPT-11 in Mice: Identification and Analysis of a Highly Effective Plasma Esterase Cancer Res., August 1, 2000; 60(15): 4206 - 4210. [Abstract] [Full Text]

				J. Thompson, E. O. George, C. A. Poquette, P. J. Cheshire, L. B. Richmond, S. S. N. de Graaf, M. Ma, C. F. Stewart, and P. J. Houghton Synergy of Topotecan in Combination with Vincristine for Treatment of Pediatric Solid Tumor Xenografts Clin. Cancer Res., November 1, 1999; 5(11): 3617 - 3631. [Abstract] [Full Text] [PDF]